Trademark/Service Mark Application, Principal Register
PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER
Principal
APPLICANT INFORMATION
*OWNER OF MARK
CRISPR Therapeutics AG
*MAILING ADDRESS
Baarerstrasse 14
*CITY
ZUG V8 SWITZERLAND
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
Switzerland
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
6300
*EMAIL ADDRESS
XXXX
LEGAL ENTITY INFORMATION
TYPE
aktiengesellschaft
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY WHERE LEGALLY ORGANIZED
Switzerland
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS
041
*IDENTIFICATION
Education services, namely, providing on-line non-downloadable articles and newsletters in the field of pharmaceuticals, genetics, genome
editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy.
FILING BASIS
SECTION 1(b)
INTERNATIONAL CLASS
042
*IDENTIFICATION
Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and
development of therapeutics pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory
services; custom cell-line engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation,
transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of
pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy;
scientific research and development services relating to targeting genetic therapies to individuals.
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Trademark/Service Mark Application, Principal Register
Serial Number:97635372
Filing Date:10/17/2022
To the Commissioner for Trademarks:
MARK: DE&I IT'S IN OUR DNA (Standard Characters, see mark)
The literal element of the mark consists of DE&I IT'S IN OUR DNA. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, CRISPR Therapeutics AG, a aktiengesellschaft legally organized under the laws of Switzerland, having an address of
Baarerstrasse 14
ZUG V8 SWITZERLAND 6300
Switzerland
XXXX
requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C.
Section 1051 et seq.), as amended, for the following:
International Class 041: Education services, namely, providing on-line non-downloadable articles and newsletters in the field of pharmaceuticals, genetics, genome editing, gene editing, genome
engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
International Class 042: Scientific research and development, namely, gene editing for researching and developing human cells and pharmaceuticals; research and development of therapeutics
pharmaceuticals using gene editing; pharmaceutical, medical, scientific, and biopharmaceutical research and development; medical laboratory services; scientific laboratory services; custom cell-line
engineering services; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation,
transcriptional modulation, genetic diseases, gene therapy and cell therapy; providing medical research and scientific research information in the fields of pharmaceuticals, genetics, genome editing,
gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy; scientific research and development
services relating to targeting genetic therapies to individuals.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
The owner's/holder's proposed attorney information: Tiffany D. Gehrke. Tiffany D. Gehrke of Marshall, Gerstein & Borun LLP, is a member of the XX bar, admitted to the bar in XXXX, bar
membership no. XXX, is located at
6300 Willis Tower
233 South Wacker Drive
Chicago, Illinois 60606
United States
312-474-6300(phone)
docket@marshallip.com
The docket/reference number is 33324/60056.
Tiffany D. Gehrke submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S.
Commonwealth or territory.
The applicant's current Correspondence Information:
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed,
and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).
Declaration
Declaration Signature
Signature: /Anders Kassow/ Date: 10/17/2022
Signatory's Name: Anders Kassow
Signatory's Position: Executive Director, Intellectual Property
Signatory's Phone Number: Not Provided
Signature method: Sent to third party for signature
Payment Sale Number: 97635372
Payment Accounting Date: 10/17/2022
Serial Number: 97635372
Internet Transmission Date: Mon Oct 17 17:37:35 ET 2022
TEAS Stamp: USPTO/BAS-XX.XXX.XX.XXX-2022101717373626
0928-97635372-820f5ff735a85f971e5ad73ed8
55e6df8f4e8da179b657511dec74da8ccc623b5b
0-CC-37351992-20221014154159192495